Project 466126

The COVID-19 pandemic has spread quickly around the world and has had unprecedented effects on societies, including disease management and health care systems. COVID-19 was described initially as a respiratory disease. However, it is increasingly recognized as a neurological disease. Furthermore, even if people with Alzheimer disease (AD) do not contract COVID-19, they are at high risk for worsening neuropsychiatric symptoms aggravated by social isolation, psychosocial stressors and disruption in the healthcare system. Definitively, the interaction between COVID-19, AD and a vulnerable healthcare system exposed people with AD and their caregivers to a higher risk of poor health outcomes compared to other population groups. While Information and Communication Technologies (ICTs) have led to the development of new remote applications and platforms for telehealth, these applications and platforms must conform to specific clinical conditions, such as ensuring privacy and security. They must also ensure a patient and their caregivers' ongoing engagement and involvement with the clinician, using these platforms. This working group brings together an international clinical and research team with complementary expertise, to work on Alzheimer's care and research. The objectives and expected results are: 1. Expert consensus on the biomarkers that are still relevant and their implementation in the process of early diagnosis using telehealth. 2. Identification of the challenges induced by COVID-19 that are related to the acceleration of the use of telehealth for people living with AD and recommendations for better telehealth appropriation by patients and their caregivers. 3. Implementation guide of new models of care for AD based on telehealth and empowerment of patients and caregivers.